|
Copyright © 2008 Faculty of Tropical Medicine, Mahidol University. All rights reserved.
Webmaster : tmwww@mahidol.ac.th |
||
| A phase 3 randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and a safety of pimodivir in combination with the standard-of-care treatment in adolescent, adult, and elderly non-hospitalized subjects with influenza A infection who are at risk of developing complications (FLZ3002)
|
|
| Antibody persistence at 3 years after a single dose vaccination of acellular pertussis vaccines containing genetically-detoxified pertussis toxin
|
|
| HPV Vaccine effectiveness after 5 years of vaccination
|
|
| A randomized, observer-blind, active comparator controlled, multicenter, phase 3 study to assess the efficacy, safety, and immunogenicity of a plant-derived Quadrivalent VLP influenza vaccine in adults 65 years of age and older
|
|
| A randomized, observer-blind, placebo-controlled, multicenter, phase 3 study to assess the efficacy, safety, and immunogenicity of a Plant-derived Quadrivalent VLP influenza vaccine in adults 18-64 years of age
|
|
| A Phase 1/2a Study to evaluate the safety/tolerability and immunogenicity of homologous Ad26 mosaic vector vaccine regimens or Ad26 mosaic and MVA mosaic heterologous vector vaccine regimens, with high-dose, low-dose or no clade C gp140 protein plus adjuvant for HIV prevention
|
|
| A phase II/III double blinded, randomized controlled, non-inferiority trial to evaluate the safety and immunogenicity of Tri fluvac, a seasonal trivalent inactivated split virion influenza vaccine, in healthy THAI subjects aged 18-49 years
|
|
| Medical and economic burden of healthcare services for immigrants at Phaholpolpayuhasena hospital, Kanchanaburi
|
|
| Antibody persistence at 2 years after a single dose vaccination of acellular pertussis vaccines among Thai adolescents
|
|
| A phase II/III randomized, observer-blind, controlled study to demonstrate non-inferior immunogenicity of a combined Tetanus-diphtheria-acellular Pertussis vaccine as compared to Adacel® vaccine in healthy subjects aged 12-17 years.
|
|
| A Phase 1/2 Randomized Double Blind Control Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 years to 49 years and Adolescents Aged Between 12 years to <18 years.
|
|
| Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX® B/E) formulated in L(MPLA) and alum in a Prime-Boost Regimen in HIV-uninfected Adults in Thailand, Uganda and Mozambique
|
|
| A phase 1/2a study to evaluate the safety/tolerability and immunogenicity of homologous Ad26 Mosaic vector vaccine regimens or Ad26 Mosaic and MVA Mosaic heterologous vector vaccine regimens, with high-dose, low-dose or no Clade C gp140 protein plus adjuvant for HIV prevention
|
|
| Evaluation of Priming effects by Pandemic Live Attenuated Influenza Vaccine (LAIV candidate vaccine strain A/17/turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study
|
|
| A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, administered in Preadolescents and Adolescents (9 to 14 year olds) with a Comparison to Young Women (16 to 26 year olds) who receive 3-dose regimen
|
|
| Acceptability of an influenza vaccine among the elderly in Bangkok and surrounding provinces, Thailand
|
|
| Community Engagement Program to Assess and Prepare Muang District Community in Nakhon Phanom Province for Participation in a Phase III Government Pharmaceutical Organization (GPO) Seasonal Trivalent Live Attenuated Influenza Vaccine Trial
|
|
| Capability Assessment for Supporting Research and Development of Vaccine in Thailand
|
|
| Randomized Double-Blind Placebo Controlled Phase III Trial to Assess the Clinical Efficacy and Safety of Government Pharmaceutical Organization (GPO) Seasonal Trivalent Live Attenuated Influenza Vaccine among Children Aged 2-18 Years
|
|
| Phase I safety and immunogenicity of live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 (H5N2) in healthy Thai volunteers
|
|
| Randomized,Double Blind Evaluation of Different One-Year Boosts after Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX® B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults
|
|
| Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Participants in the HIV Vaccine Efficacy Trial RV144: “Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX B/E) Boosting in HIV-uninfected Thai Adults
|
|
| Efficacy and safety of a novel Tetravalent Dengue vaccine in healthy children aged 2 to 14 years in Asia
|
|
| Safety, Immunogenity and Efficacy Studies of WRSS1, a Live Attenuated Shigella sonnei Vaccine Candidate, in Healthy Thai Adults
|
|
| Prospective surveillance of febrile illness for dengue-endemic areas in Asia
|
|
| Phase I/II safety and immunogenicity of pandemic live attenuated influenza vaccine (PLAIV) candidate strain A/17/CA/2009/38 (H1N1) in healthy Thais
|
|
| A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 year olds) with a Comparison to Young Women (16 to 26 year olds)
|
|
| A bioequivalence study of two formulations of 16 mg Candesartan tablets in healthy Thai volunteers
|
|
| Measurement of Anogenital Wart Burden and Cost of Illnesses in Thailand
|
|
| A Phase 2b/3, randomized, double blind, dose confirming study of the safety, efficacy and tolerability of apricitabine versus lamivudine in treatment-experienced HIV-1 infected patients with the M184V mutation in reverse transcriptase.
|
|
| Measuring Herpes Zoster and Post-Herpetic Neuralgia Associated Burden of Illness and Health Care Utilcation and Costs in Thailand
|
|
| Assessing the psychosocial burden in women with an abnormal pap results after screening interventions.
|
|
| Establishment of a Shigella sonnei Challenge Model for Evaluation of Future Vaccine Candidates
|
|
| A study to evaluate the efficacy of GARDASILTM (Human Papillomavirus [types 6,11,16,18] recombinanat vaccine) in reducing the incidence of HPV 6-,11-,16-, and 18- related CIN, AIS, and cervical cancer, and HPV 6-,11-,16-, and 18-related external genital warts, VIN, VaIN, vulvar cancer, and vaginal cancer in 26- to- 45 year-old women
|
|
| A cross-sectional study to screen for and generate broady neutralizing monoclonal antibodies from HIV infected individuals.
|
|
| Phase III HIV – 1 Preventive Vaccine Trial, “A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC- HIV (vCP 1521) Priming with Vaxgen gp120 B/E (AIDSVAX® B/E) Boosting in HIV- un infected Thai Adults”.
|
|
| A World-wide Phase I, Dose-escalating Study of the Safety, Tolerability and Immunogenicity of a 3-Dose Regimen of the MRKAd 5 HIV-1 gag Vaccine in healthy adults.
|
|
| A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASILTM, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16-to-26-Year-Old Women
|
|
| Safety and Therapeutic Effects of Jin Huang Chinese Medicine in Uncomplicated HIV – 1 Patients.
|
|
| Open-Label, Treatment Protocol for the Safety and Efficacy of SCH 56592 (Oral Suspension) in the Treatment of Invasive Fungal Infections
|
|
| Observational Probe Study of In Vitro Immune Response Parameters to Candidate HIV – 1 Vaccine Antigens among Subjects in Thailand.
|
|
| A Retrospective Study to Establish a Historical Database on the Efficacy of Standard Antifungal Therapy in Patients with Invasive Fungal Infection.
|
|
| A Phase III Trial to Determine the Efficacy of AIDSVAXTM B/E Vaccine in IVDUs in Bangkok, Thailand.
|
|
| A multicenter, randomized, double-blind, phase II study to evaluate the safety, tolerance and efficacy of multiple doses of SCH 56592 versus fluconazole in the treatment of oropharyngeal candidiasis (OPC) in HIV-positive patients
|
|
| Phase I/II trial of Pasteur Merieux Connaught (PMC) live recombinant ALVAC – HIV (vCP1521) Priming with Vaxgen gp 120 B/E (AIDSV AXTM B/E) Boost in Thai HIV – Seronegative Adults
|
|
| Cholera Challenge in volunteers using frozen V. cholera 0139 bacteria for challenge
|
|
| A Phase I/II Double-blind, Placebo-controlled study of the Chiron Biocine HIV Thai E gp 120/MF 59 Vaccine Administered alone or combined with The Chiron Biocine HIV SF 2 gp 120 Antigen in healthy HIV-seronegative Thai Adults.
|
|
Copyright © 2008 Faculty of Tropical Medicine, Mahidol University. All rights reserved.
Webmaster : tmwww@mahidol.ac.th |
||
Facebook